Companies with late-stage peptide drugs
47 companies hold rights to 49 peptide drugs (peptide drugs, oral and injected) that are in Phase 3, Phase 2/3 or filed for approval. Sorted by the number of such drugs, then by name. Approved drugs are not counted. The full directory, with financials, is on the companies page.
| Company | Ticker | Late-stage | Drugs (stage, indications) |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals | 600276 | 5 | HR17031 (Phase 3, Type 2 Diabetes); Insulin sudelidec (INS068) (Phase 3, Type 2 Diabetes); Noiiglutide (Phase 3, Type 2 Diabetes); ribupatide (Phase 3, Obesity, Type 2 Diabetes, Heart Failure and more); SHR-3167 (Phase 3, Type 2 Diabetes) |
| Novo Nordisk | NVO | 5 | cagrilintide (Phase 3, Obesity, Type 2 Diabetes, Chronic Kidney Disease); cagrilintide/semaglutide (Phase 3, Obesity, Type 2 Diabetes); IcoSema (Phase 3, Type 2 Diabetes); UBT251 (Phase 3, Obesity, Type 2 Diabetes, Chronic Kidney Disease); zenagamtide (Phase 3, Obesity, Type 2 Diabetes) |
| Eli Lilly | LLY | 4 | Brenipatide (Phase 3, Obesity, Major Depressive Disorder, Chronic Obstructive Pulmonary Disease and more); eloralintide (Phase 3, Obesity, Osteoarthritis); mazdutide (Phase 3, Obesity, Type 2 Diabetes); retatrutide (Phase 3, Obesity, Type 2 Diabetes, Chronic Kidney Disease and more) |
| Hansoh Pharmaceutical Group | 3692 | 3 | olatorepatide (Phase 3, Obesity, Type 2 Diabetes, Hidradenitis Suppurativa); Pegloxenatide (Fulaimei) (Phase 3, Type 2 Diabetes); Pegmolesatide (HS-20039) (Phase 3, Chronic Kidney Disease) |
| AstraZeneca | AZN | 2 | Eneboparatide (Phase 3, Hypoparathyroidism); Lenbelintide (Phase 3, Obesity) |
| Gan & Lee Pharmaceuticals | 603087 | 2 | Bofanglutide (Phase 3, Obesity, Type 2 Diabetes); GZR33 (Phase 3, Type 2 Diabetes) |
| Hangzhou Zhongmei Huadong Pharmaceutical | 000963 | 2 | HDG1901 (Phase 3, Type 2 Diabetes); HDM1005 (Phase 3, Obesity, Type 2 Diabetes) |
| Pfizer | PFE | 2 | Berobenatide (Phase 3, Obesity, Type 2 Diabetes); ecnoglutide (Phase 3, Obesity, Type 2 Diabetes, Osteoarthritis) |
| Roche | RHHBY | 2 | enicepatide (Phase 3, Obesity, Type 2 Diabetes); petrelintide (Phase 3, Obesity) |
| Zealand Pharma | ZEAL | 2 | petrelintide (Phase 3, Obesity); survodutide (Phase 3, Obesity, Type 2 Diabetes, MASH / NASH) |
| A. Menarini | — | 1 | Bofanglutide (Phase 3, Obesity, Type 2 Diabetes) |
| Adocia | ADOC | 1 | THDB0206 (Phase 3, Type 2 Diabetes) |
| Altimmune | ALT | 1 | pemvidutide (Phase 3, MASH / NASH) |
| Amgen | AMGN | 1 | maridebart cafraglutide (Phase 3, Obesity, Type 2 Diabetes, Heart Failure and more) |
| Amylyx Pharmaceuticals, Inc. | AMLX | 1 | avexitide (Phase 3, Post-Bariatric Hypoglycemia) |
| Beijing QL Biopharmaceutical | — | 1 | zovaglutide (Phase 3, Obesity) |
| BioMarin Pharmaceutical | BMRN | 1 | BMN 333 (Phase 2/3, Achondroplasia) |
| Boehringer Ingelheim | — | 1 | survodutide (Phase 3, Obesity, Type 2 Diabetes, MASH / NASH) |
| BrightGene Bio-Medical Technology | 688166 | 1 | BGM0504 (Phase 3, Obesity, Type 2 Diabetes) |
| China Resources Sanjiu Medical & Pharmaceutical | 000999 | 1 | BGM0504 (Phase 3, Obesity, Type 2 Diabetes) |
| Chugai Pharma | 4519 | 1 | enicepatide (Phase 3, Obesity, Type 2 Diabetes) |
| ConjuChem | — | 1 | Albenatide (Phase 3, Type 2 Diabetes) |
| Everest Medicines (Beijing) Co., Ltd. | 1952 | 1 | MT1013 (Phase 3, Chronic Kidney Disease, Secondary Hyperparathyroidism) |
| Frontier Biotechnologies | 688221 | 1 | Albuvirtide (Phase 3, HIV) |
| GemVax & KAEL | 082270 | 1 | Tertomotide (Phase 3, Alzheimer's Disease, Pancreatic Cancer) |
| Guangdong Raynovent Biotech | — | 1 | RAY1225 (Phase 3, Obesity, Type 2 Diabetes) |
| Haisco Pharmaceutical Group | 002653 | 1 | Anrikefon (HSK21542) (Phase 3, Chronic Kidney Disease) |
| Hanmi Pharmaceutical | 128940 | 1 | efpeglenatide (Phase 3, Obesity, Type 2 Diabetes) |
| Hebei Changshan Biochemical Pharmaceutical Co., Ltd | 300255 | 1 | Albenatide (Phase 3, Type 2 Diabetes) |
| Innovent Biologics | 1801 | 1 | mazdutide (Phase 3, Obesity, Type 2 Diabetes) |
| Ironwood Pharmaceuticals | IRWD | 1 | apraglutide (Phase 3, Short Bowel Syndrome) |
| JW Pharmaceutical | 001060 | 1 | Bofanglutide (Phase 3, Obesity, Type 2 Diabetes) |
| Kailera Therapeutics | KLRA | 1 | ribupatide (Phase 3, Obesity, Type 2 Diabetes, Heart Failure and more) |
| Laboratorios Sanfer | — | 1 | efpeglenatide (Phase 3, Obesity, Type 2 Diabetes) |
| Lifeward Ltd. | LFWD | 1 | ORMD-0801 (Phase 3, Type 2 Diabetes, MASH / NASH) |
| Lupin Limited | LUPIN | 1 | Bofanglutide (Phase 3, Obesity, Type 2 Diabetes) |
| Merck & Co. | MRK | 1 | Enlicitide (Phase 3, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia) |
| Palatin Technologies | PTN | 1 | PL9643 (Phase 3, Dry Eye Disease) |
| PegBio | 2565 | 1 | Visepegenatide (PB-119) (Phase 3, Type 2 Diabetes) |
| Qilu Pharmaceutical | — | 1 | RAY1225 (Phase 3, Obesity, Type 2 Diabetes) |
| Regeneron Pharmaceuticals | REGN | 1 | olatorepatide (Phase 3, Obesity, Type 2 Diabetes, Hidradenitis Suppurativa) |
| Sciwind Biosciences | — | 1 | ecnoglutide (Phase 3, Obesity, Type 2 Diabetes, Osteoarthritis) |
| Shaanxi Micot Pharmaceutical Technology | 2335 | 1 | MT1013 (Phase 3, Chronic Kidney Disease, Secondary Hyperparathyroidism) |
| Shanghai HEP Pharmaceutical | — | 1 | hepalatide (Phase 3, Chronic Hepatitis B, Chronic Hepatitis Delta) |
| Tonghua Dongbao Pharmaceutical | 600867 | 1 | THDB0206 (Phase 3, Type 2 Diabetes) |
| United Bio-Technology (Hengqin) | — | 1 | UBT251 (Phase 3, Obesity, Type 2 Diabetes, Chronic Kidney Disease) |
| Viking Therapeutics | VKTX | 1 | VK2735 (Phase 3, Obesity, Type 2 Diabetes) |
Stage is the furthest stage the drug has reached in any indication. Kind follows each drug's recorded modality; a drug whose modality is not recorded is left out.